Phase II trial of carboplatin and vinblastine in advanced squamous-cell carcinoma of the head and neck

A chemotherapy regimen consisting of carboplatin and vinblastine was given to 30 patients with recurrent or previously untreated, locally advanced squamous carcinoma of the head and neck region. The main aim of the study was to assess the toxicity of this regimen, the feasibility of its outpatient a...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 1990-01, Vol.26 (6), p.464-466
Main Authors: EL SAYED, S, SYMONDS, R. P, ROBERTSON, A. G, PAUL, J, MCGARVA, J
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Carboplatin - administration & dosage
Carboplatin - adverse effects
Carcinoma, Squamous Cell - drug therapy
Chemotherapy
Drug Evaluation
Female
Head and Neck Neoplasms - drug therapy
Humans
Lymphatic Metastasis
Male
Medical sciences
Metoclopramide - administration & dosage
Middle Aged
Pharmacology. Drug treatments
Remission Induction
Time Factors
Vinblastine - administration & dosage
Vinblastine - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A chemotherapy regimen consisting of carboplatin and vinblastine was given to 30 patients with recurrent or previously untreated, locally advanced squamous carcinoma of the head and neck region. The main aim of the study was to assess the toxicity of this regimen, the feasibility of its outpatient administration and the tumour response. A total of ten patients (33%) achieved an objective response, including two who achieved a complete response. The combination offered useful palliation for patients with recurrent disease; it was well tolerated and can be given on an outpatient basis. This regimen could be combined with other active agents such as methotrexate or bleomycin.
ISSN:0344-5704
1432-0843
DOI:10.1007/BF02994101